5
|
Lelais G, Epple R, Marsilje TH, Long YO, McNeill M, Chen B, Lu W, Anumolu J, Badiger S, Bursulaya B, DiDonato M, Fong R, Juarez J, Li J, Manuia M, Mason DE, Gordon P, Groessl T, Johnson K, Jia Y, Kasibhatla S, Li C, Isbell J, Spraggon G, Bender S, Michellys PY. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers. J Med Chem 2016; 59:6671-89. [DOI: 10.1021/acs.jmedchem.5b01985] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Gérald Lelais
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Robert Epple
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Thomas H. Marsilje
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Yun O. Long
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Matthew McNeill
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Bei Chen
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Wenshuo Lu
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Jaganmohan Anumolu
- Aurigene Discovery Technologies, Bollaram Road, Miyapur, Hyderabad 500 049, India
| | - Sangamesh Badiger
- Aurigene Discovery Technologies, 39-40, Electronic City Phase 2, Bangalore 560 100, India
| | - Badry Bursulaya
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Michael DiDonato
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Rina Fong
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Jose Juarez
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Jie Li
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Mari Manuia
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Daniel E. Mason
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Perry Gordon
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Todd Groessl
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Kevin Johnson
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Yong Jia
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Shailaja Kasibhatla
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Chun Li
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - John Isbell
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Glen Spraggon
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Steven Bender
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| | - Pierre-Yves Michellys
- Genomics Institute of the Novartis Research Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States
| |
Collapse
|
9
|
Wurz RP, Pettus LH, Ashton K, Brown J, Chen JJ, Herberich B, Hong FT, Hu-Harrington E, Nguyen T, St. Jean DJ, Tadesse S, Bauer D, Kubryk M, Zhan J, Cooke K, Mitchell P, Andrews KL, Hsieh F, Hickman D, Kalyanaraman N, Wu T, Reid DL, Lobenhofer EK, Andrews DA, Everds N, Guzman R, Parsons AT, Hedley SJ, Tedrow J, Thiel OR, Potter M, Radinsky R, Beltran PJ, Tasker AS. Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. ACS Med Chem Lett 2015; 6:987-92. [PMID: 26396685 DOI: 10.1021/acsmedchemlett.5b00193] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Accepted: 07/27/2015] [Indexed: 01/26/2023] Open
Abstract
In nonsmall cell lung cancer (NSCLC), the threonine(790)-methionine(790) (T790M) point mutation of EGFR kinase is one of the leading causes of acquired resistance to the first generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Herein, we describe the optimization of a series of 7-oxopyrido[2,3-d]pyrimidinyl-derived irreversible inhibitors of EGFR kinase. This led to the discovery of compound 24 which potently inhibits gefitinib-resistant EGFR(L858R,T790M) with 100-fold selectivity over wild-type EGFR. Compound 24 displays strong antiproliferative activity against the H1975 nonsmall cell lung cancer cell line, the first line mutant HCC827 cell line, and promising antitumor activity in an EGFR(L858R,T790M) driven H1975 xenograft model sparing the side effects associated with the inhibition of wild-type EGFR.
Collapse
Affiliation(s)
- Ryan P. Wurz
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Liping H. Pettus
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Kate Ashton
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - James Brown
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jian Jeffrey Chen
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Brad Herberich
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Fang-Tsao Hong
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Essa Hu-Harrington
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Tom Nguyen
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - David J. St. Jean
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Seifu Tadesse
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - David Bauer
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Michele Kubryk
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jinghui Zhan
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Keegan Cooke
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Petia Mitchell
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Kristin L. Andrews
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Faye Hsieh
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Dean Hickman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Nataraj Kalyanaraman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Tian Wu
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Darren L. Reid
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Edward K. Lobenhofer
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Dina A. Andrews
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Nancy Everds
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Roberto Guzman
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Andrew T. Parsons
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Simon J. Hedley
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Jason Tedrow
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Oliver R. Thiel
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Matthew Potter
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Robert Radinsky
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Pedro J. Beltran
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| | - Andrew S. Tasker
- Medicinal Chemistry, ‡Oncology Research, §Molecular Structure, ∥Pharmacokinetics and Drug Metabolism, ⊥Oral Delivery − Product and Process Development, ○Discovery Toxicology, #Pathology, ▽Chemical Process R&D, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
- Medicinal Chemistry, +Chemical Process R&D, ∞Analytical R&D, Amgen Inc., 360 Binney Avenue, Cambridge, Massachusetts 02142-1011, United States
| |
Collapse
|
12
|
Tjin Tham Sjin R, Lee K, Walter AO, Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R, Karp R, Medikonda A, Chaturvedi P, Ren Y, Haringsma H, Etter J, Raponi M, Simmons AD, Harding TC, Niu D, Nacht M, Westlin WF, Petter RC, Allen A, Singh J. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol Cancer Ther 2014; 13:1468-79. [PMID: 24723450 DOI: 10.1158/1535-7163.mct-13-0966] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib. However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approximately 60% of all resistance. Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFR(WT)). These inhibitors have not provided compelling clinical benefit in T790M-positive patients, apparently because of dose-limiting toxicities associated with inhibition of EGFR(WT). Thus, there is an urgent clinical need for therapeutics that overcome T790M drug resistance while sparing EGFR(WT). Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compounds that are EGFR mutant (EGFR(mut)) selective and have been designed to have low affinity for EGFR(WT). Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation. Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFR(WT). Of all the compounds tested, compound 3 displayed the best efficacy in EGFR(L858R/T790M)-driven tumors. Compound 3, now renamed CO-1686, is currently in a phase I/II clinical trial in patients with EGFR(mut)-advanced NSCLC that have received prior EGFR-directed therapy.
Collapse
Affiliation(s)
- Robert Tjin Tham Sjin
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Kwangho Lee
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Annette O Walter
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Aleksandr Dubrovskiy
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Michael Sheets
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Thia St Martin
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Matthew T Labenski
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Zhendong Zhu
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Richland Tester
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Russell Karp
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Aravind Medikonda
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Prasoon Chaturvedi
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Yixuan Ren
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Henry Haringsma
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Jeff Etter
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Mitch Raponi
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Andrew D Simmons
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Thomas C Harding
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Deqiang Niu
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Mariana Nacht
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - William F Westlin
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Russell C Petter
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Andrew Allen
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| | - Juswinder Singh
- Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California
| |
Collapse
|